Afonso Fernandes
Overview
Explore the profile of Afonso Fernandes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandes A, Ferreira S, Moreira P, Machado-Sousa M, Couto B, Raposo-Lima C, et al.
Front Public Health
. 2024 Feb;
12:1333997.
PMID: 38414900
Introduction: The COVID-19 outbreak and the community mitigation strategies implemented to reduce new SARS-CoV-2 infections can be regarded as powerful stressors with negative consequences on people's mental health. Although it...
2.
Peixoto C, Lopes M, Martins M, Casimiro S, Sobral D, Grosso A, et al.
BMC Bioinformatics
. 2023 Jan;
24(1):17.
PMID: 36647008
Colorectal cancer (CRC) is the third most common cancer and the second most deathly worldwide. It is a very heterogeneous disease that can develop via distinct pathways where metastasis is...
3.
Sobral D, Martins M, Kaplan S, Golkaram M, Salmans M, Khan N, et al.
Commun Biol
. 2022 Sep;
5(1):937.
PMID: 36085309
Colorectal cancer (CRC) is a highly diverse disease, where different genomic instability pathways shape genetic clonal diversity and tumor microenvironment. Although intra-tumor heterogeneity has been characterized in primary tumors, its...
4.
Costa A, Fernandes A, Ferreira S, Couto B, Machado-Sousa M, Moreira P, et al.
Int J Environ Res Public Health
. 2022 Feb;
19(4).
PMID: 35206431
During the first COVID-19 related confinement in Portugal, there was a decrease in the levels of psychological symptoms measured by the Depression, Anxiety and Stress Scale 21 (March to April...
5.
Cruz-Duarte R, de Almeida C, Negrao M, Fernandes A, Borralho P, Sobral D, et al.
Clin Cancer Res
. 2022 Jan;
28(6):1203-1216.
PMID: 34980600
Purpose: Cetuximab is an EGFR-targeted therapy approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC). However, about 60% of these patients show innate resistance to cetuximab. To...
6.
Golkaram M, Salmans M, Kaplan S, Vijayaraghavan R, Martins M, Khan N, et al.
NPJ Genom Med
. 2021 Feb;
6(1):13.
PMID: 33589643
Colorectal cancer (CRC) is one of the most lethal malignancies. The extreme heterogeneity in survival rate is driving the need for new prognostic biomarkers. Human endogenous retroviruses (hERVs) have been...
7.
Tato-Costa J, Casimiro S, Pacheco T, Pires R, Fernandes A, Alho I, et al.
Clin Colorectal Cancer
. 2015 Nov;
15(2):170-178.e3.
PMID: 26603055
Introduction: DNA damaging agents and ionizing radiation used in the therapy of human cancers can induce senescence of cancer cells. Senescent cells exhibit a secretory phenotype (senescence-associated secretome [SAS]) that...
8.
Casimiro S, Fernandes A, Oliveira A, Franco M, Pires R, Peres M, et al.
Clin Exp Metastasis
. 2014 Jun;
31(6):689-96.
PMID: 24946951
Colorectal cancer (CRC) is the third most common malignant disease in men and the second in women worldwide. CRC relapse occurs mostly in liver and lungs, decreasing the 5-year survival...
9.
Fernandes I, Pacheco T, Costa A, Santos A, Fernandes A, Santos M, et al.
Onco Targets Ther
. 2012 Dec;
5:409-16.
PMID: 23226698
Introduction: Somatostatin analogs (SSAs) are used as part of standard treatment for advanced neuroendocrine tumors (NETs). The mechanisms behind the antiproliferative action of SSAs remain largely unknown, but a connection...
10.
D B Bordalo A, Alves I, Nobre A, Silva F, Lemos A, Serpa C, et al.
Rev Port Cardiol
. 2012 Jul;
31(9):567-75.
PMID: 22832502
Unlabelled: Easy access to echocardiography and its extensive and repeated use (as is the case in Portugal) now facilitates the early diagnosis of cardiac myxoma (CM). Objective: To re-evaluate the...